Loss of has-miR-337-3p expression is associated with lymph node metastasis of human gastric cancer

Journal of Experimental & Clinical Cancer Research

Qiong Wu³  Yumei Li³  Rui Wang³  Bo Hao¹  Yan Yang³  Jin Wang²  Zishu Wang³ 

[1] Department of Gastrointestinal Surgery, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233004, China;Department of Oncology, Changzheng Hospital, The Second Military Medical University, Shanghai 200433, China;Department of Medical Oncology, The First Affiliated Hospital of Bengbu Medical College, 287 Changhuai Road, Bengbu 233004, Anhui, China

关键词: miRNA array;    hsa-miR-337-3p;    Metastasis;    miRNA;    Gastric cancer;   

Others  :  815050
DOI  :  10.1186/1756-9966-32-76

 received in 2013-07-26, accepted in 2013-10-02,  发布年份 2013

【 摘 要 】

Background

Metastasis is the major cause of cancer-related death in patients with gastric cancer, and aberrant expression of various microRNAs (miRNAs) is associated with cancer metastasis.

Methods

Profiling of differentially expressed miRNAs was performed in three cases of primary gastric cancer and the corresponding metastatic lymph node tissues. Then, the five most altered miRNAs were further verified in 16 paired samples. Two of these five miRNAs were further assessed for their effects on the regulation of gastric cancer cell growth and invasion.

Results

The miRNA profile data showed 151 upregulated miRNAs (≥ 1.5-fold) and 285 downregulated miRNAs (≤ 0.67-fold) in the metastatic tissues compared to the primary gastric cancer tissues. Among these five miRNAs (i.e., hsa-miR-508-5p, hsa-miR-30c, hsa-miR-337-3p, hsa-miR-483-5p, and hsa-miR-134), expression of hsa-miR-337-3p and hsa-miR-134 was significantly downregulated in these 16 lymph node metastatic tissues compared to their primary tumor tissues (P<0.05) and in nine gastric cancer cell lines compared to the nonmalignant GES cell line. Furthermore, induction of hsa-miR-134 or hsa-miR-337-3p expression did not dramatically affect gastric cancer cell proliferation, but transfection of the hsa-miR-337-3p mimic did reduce gastric cancer cell invasion capacity.

Conclusions

These findings indicate that hsa-miR-337-3p plays a role in the reduction of gastric cancer cell invasion capacity, and further studies on the mechanism of hsa-miR-337-3p in gastric cancer metastasis are warranted.

【 授权许可】

   
2013 Wang et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Wang J, Yu JC, Kang WM, Ma ZQ: Treatment strategy for early gastric cancer. Surg Oncol 2012, 21:119-123.
• [2]Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917.
• [3]Kamangar F, Dores GM, Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006, 24:2137-2150.
• [4]Kim DW, Park SA, Kim CG: Detecting the recurrence of gastric cancer after curative resection: comparison of FDG PET/CT and contrast-enhanced abdominal CT. J Korean Med Sci 2011, 26:875-880.
• [5]Rohatgi PR, Yao JC, Hess K, Schnirer I, Rashid A, Mansfield PF, Pisters PW, Ajani JA: Outcome of gastric cancer patients after successful gastrectomy: influence of the type of recurrence and histology on survival. Cancer 2006, 107:2576-2580.
• [6]Wienholds E, Plasterk RH: MicroRNA function in animal development. FEBS Lett 2005, 579:5911-5922.
• [7]Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
• [8]Zhao X, Yang L, Hu J: Down-regulation of miR-27a might inhibit proliferation and drug resistance of gastric cancer cells. J Exp Clin Cancer Res 2011, 30:55. BioMed Central Full Text
• [9]Jay C, Nemunaitis J, Chen P, Fulgham P, Tong AW: miRNA profiling for diagnosis and prognosis of human cancer. DNA Cell Biol 2007, 26:293-300.
• [10]Ma RM, Jiang T, Kang XX: Circulating microRNAs in cancer: origin, function and application. J Exp Clin Canc Res 2012, 31:38. BioMed Central Full Text
• [11]Li BS, Zhao YL, Guo G, Li W, Zhu ED, Luo X, Mao XH, Zou QM, Yu PW, Zuo QF, et al.: Plasma microRNAs, miR-223, miR-21 and miR-218, as novel potential biomarkers for gastric cancer detection. PLoS One 2012, 7:e41629.
• [12]Kang W, Tong JH, Chan AW, Lung RW, Chau SL, Wong QW, Wong N, Yu J, Cheng AS, To KF: Stathmin1 plays oncogenic role and is a target of microRNA-223 in gastric cancer. PLoS One 2012, 7:e33919.
• [13]Xu Y, Sun J, Xu J, Li Q, Guo Y, Zhang Q: miR-21 is a promising novel biomarker for lymph node metastasis in patients with gastric cancer. Gastroenterol Res Pract 2012, 2012:640168.
• [14]Wang M, Li C, Nie H, Lv X, Qu Y, Yu B, Su L, Li J, Chen X, Ju J, et al.: Down-regulated miR-625 suppresses invasion and metastasis of gastric cancer by targeting ILK. FEBS Lett 2012, 586:2382-2388.
• [15]Martin-Perez D, Vargiu P, Montes-Moreno S, Leon EA, Rodriguez-Pinilla SM, Lisio LD, Martinez N, Rodriguez R, Mollejo M, Castellvi J, et al.: Epstein-Barr virus microRNAs repress BCL6 expression in diffuse large B-cell lymphoma. Leukemia 2012, 26:180-183.
• [16]Wang YX, Zhang XY, Zhang BF, Yang CQ, Chen XM, Gao HJ: Initial study of microRNA expression profiles of colonic cancer without lymph node metastasis. J Dig Dis 2010, 11:50-54.
• [17]Luo HC, Zhang HB, Zhang ZZ, Zhang X, Ning B, Guo JJ, Nie N, Liu B, Wu XL: Down-regulated miR-9 and miR-433 in human gastric carcinoma. J Exp Clin Canc Res 2009, 28:82. BioMed Central Full Text
• [18]Patterson E, Webb R, Weisbrod A, Bian B, He M, Zhang L, Holloway AK, Krishna R, Nilubol N, Pacak K, et al.: The microRNA expression changes associated with malignancy and SDHB mutation in pheochromocytoma. Endocr Relat Cancer 2012, 19:157-166.
• [19]Soon PS, Tacon LJ, Gill AJ, Bambach CP, Sywak MS, Campbell PR, Yeh MW, Wong SG, Clifton-Bligh RJ, Robinson BG, et al.: miR-195 and miR-483-5p identified as predictors of poor prognosis in adrenocortical cancer. Clin Cancer Res 2009, 15:7684-7692.
• [20]Nagel S, Scherr M, Kel A, Hornischer K, Crawford GE, Kaufmann M, Meyer C, Drexler HG, MacLeod RA: Activation of TLX3 and NKX2-5 in t(5;14)(q35;q32) T-cell acute lymphoblastic leukemia by remote 3'-BCL11B enhancers and coregulation by PU.1 and HMGA1. Cancer Res 2007, 67:1461-1471.
• [21]Bezrookove V, van Zelderen-Bhola SL, Brink A, Szuhai K, Raap AK, Barge R, Beverstock GC, Rosenberg C: A novel t(6;14)(q25-q27;q32) in acute myelocytic leukemia involves the BCL11B gene. Cancer Genet Cytogenet 2004, 149:72-76.
• [22]Du L, Subauste MC, Desevo C, Zhao Z, Baker M, Borkowski R, Schageman JJ, Greer R, Yang CR, Suraokar M, et al.: miR-337-3p and its targets STAT3 and RAP1A modulate taxane sensitivity in non-small cell lung cancers. PLoS One 2012, 7:e39167.
• [23]Yin W, Cheepala S, Roberts JN, Syson-Chan K, DiGiovanni J, Clifford JL: Active Stat3 is required for survival of human squamous cell carcinoma cells in serum-free conditions. Mol Cancer 2006, 5:15. BioMed Central Full Text
• [24]Alvarez JV, Greulich H, Sellers WR, Meyerson M, Frank DA: Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor. Cancer Res 2006, 66:3162-3168.
• [25]Lin KB, Freeman SA, Gold MR: Rap GTPase-mediated adhesion and migration: a target for limiting the dissemination of B-cell lymphomas? Cell Adh Migr 2010, 4:327-332.
• [26]Hauser S, Wulfken LM, Holdenrieder S, Moritz R, Ohlmann CH, Jung V, Becker F, Herrmann E, Walgenbach-Brunagel G, von Ruecker A, et al.: Analysis of serum microRNAs (miR-26a-2*, miR-191, miR-337-3p and miR-378) as potential biomarkers in renal cell carcinoma. Cancer Epidemiol 2012, 36:391-394.
• [27]Yao Y, Suo AL, Li ZF, Liu LY, Tian T, Ni L, Zhang WG, Nan KJ, Song TS, Huang C: MicroRNA profiling of human gastric cancer. Mol Med Report 2009, 2:963-970.